ORMD-0801
ORA-D-013-2
Phase 3 small_molecule terminated
Quick answer
ORMD-0801 for T2DM (Type 2 Diabetes Mellitus) is a Phase 3 program (small_molecule) at ORAMED PHARMACEUTICALS INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ORAMED PHARMACEUTICALS INC.
- Indication
- T2DM (Type 2 Diabetes Mellitus)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated